Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSE:DNA NASDAQ:TECX NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$22.00+0.9%$21.33$89.95▼$99.05$637.67M0.9553,591 shs2.66 million shsDNAGinkgo Bioworks$10.23-0.2%$8.58$5.37▼$17.58$669.57M1.791.34 million shs1.32 million shsTECXTectonic Therapeutic$33.09+3.4%$29.12$14.39▼$36.03$603.62M3.19124,958 shs256,841 shsTLSATiziana Life Sciences$1.23+4.2%$1.31$1.04▼$2.60$150.17M0.44199,780 shs183,706 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%+30.80%+4.56%+65.91%+139.39%DNAGinkgo Bioworks+0.36%+13.50%+9.14%+67.05%+8.65%TECXTectonic Therapeutic+3.44%+9.06%+6.16%+7.05%+67.12%TLSATiziana Life Sciences+4.24%+6.96%-12.77%+5.13%-23.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$22.00+0.9%$21.33$89.95▼$99.05$637.67M0.9553,591 shs2.66 million shsDNAGinkgo Bioworks$10.23-0.2%$8.58$5.37▼$17.58$669.57M1.791.34 million shs1.32 million shsTECXTectonic Therapeutic$33.09+3.4%$29.12$14.39▼$36.03$603.62M3.19124,958 shs256,841 shsTLSATiziana Life Sciences$1.23+4.2%$1.31$1.04▼$2.60$150.17M0.44199,780 shs183,706 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%+30.80%+4.56%+65.91%+139.39%DNAGinkgo Bioworks+0.36%+13.50%+9.14%+67.05%+8.65%TECXTectonic Therapeutic+3.44%+9.06%+6.16%+7.05%+67.12%TLSATiziana Life Sciences+4.24%+6.96%-12.77%+5.13%-23.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ADNAGinkgo Bioworks 1.67Reduce$8.50-16.93% DownsideTECXTectonic Therapeutic 3.00Buy$79.40139.95% UpsideTLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TLSA, DNA, TECX, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026TECXTectonic Therapeutic Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$76.00 ➝ $81.005/6/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DNAGinkgo Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026TECXTectonic Therapeutic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ADNAGinkgo Bioworks$151.40M4.41N/AN/A$8.74 per share1.17TECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ADNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/AN/ALatest TLSA, DNA, TECX, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026DNAGinkgo Bioworks-$1.2112-$1.39-$0.1789-$1.39$42.93 million$19.00 million5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/A5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78DNAGinkgo BioworksN/A5.155.15TECXTectonic TherapeuticN/A18.5118.51TLSATiziana Life SciencesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ADNAGinkgo Bioworks78.63%TECXTectonic Therapeutic62.63%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%DNAGinkgo Bioworks12.69%TECXTectonic Therapeutic39.80%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/ATLSATiziana Life Sciences8127.26 million76.58 millionOptionableTLSA, DNA, TECX, and AVTE HeadlinesRecent News About These CompaniesTiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trialJune 25, 2026 | proactiveinvestors.comTiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS TrialJune 25, 2026 | globenewswire.comWhy Tiziana Life Sciences Is Back on the Small-Cap Radar?June 19, 2026 | kalkinemedia.comKTiziana Life Sciences Announces Purchase of Shares by Executive ChairmanJune 15, 2026 | globenewswire.comTiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkMay 29, 2026 | finanznachrichten.deTiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkMay 28, 2026 | globenewswire.comTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22, 2026 | proactiveinvestors.comTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22, 2026 | proactiveinvestors.comTiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment UpdateMay 21, 2026 | finance.yahoo.comTiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trialMay 21, 2026 | proactiveinvestors.comTiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialMay 21, 2026 | globenewswire.comTiziana Life Sciences price target boosted on foralumab updateMay 19, 2026 | proactiveinvestors.comTiziana says updated data for multiple sclerosis therapy shows long-term safetyMay 19, 2026 | seekingalpha.comTiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MSMay 19, 2026 | proactiveinvestors.comTiziana Life Sciences Ltd.: Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | finanznachrichten.deTiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | globenewswire.comTiziana Brain Trial Draws Fresh Nasdaq Index AttentionMay 16, 2026 | kalkinemedia.comKTiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trialMay 14, 2026 | proactiveinvestors.comTiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal ForalumabMay 14, 2026 | globenewswire.comTiziana Life Sciences Delays Annual 20-F FilingMay 2, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 20263 ETFs For the Coming Genomics RevolutionBy Nathan Reiff | June 7, 2026TLSA, DNA, TECX, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$22.00 +0.19 (+0.87%) As of 06/26/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Ginkgo Bioworks NYSE:DNA$10.23 -0.02 (-0.18%) Closing price 06/29/2026 03:59 PM EasternExtended Trading$10.18 -0.06 (-0.56%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Tectonic Therapeutic NASDAQ:TECX$33.09 +1.10 (+3.44%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$31.79 -1.30 (-3.94%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Tiziana Life Sciences NASDAQ:TLSA$1.23 +0.05 (+4.24%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$1.25 +0.02 (+1.95%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
